Evommune (EVMN) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Pyxis Oncology is the larger company by market cap ($240.1 million vs $225.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | PYXS |
|---|---|---|
| Share price | $6.22 | $2.01 |
| Market cap | $225.74M | $240.11M |
| 1-day change | -5.90% | -0.50% |
| YTD return | -63.67% | +74.78% |
| 1-year return | — | -21.18% |
| 5-year return | — | -82.92% |
| EPS (TTM) | $-3.75 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $5.55 |
| 52-week low | $6.08 | $1.03 |
| Distance from 52-week high | -81.27% | -63.78% |
| Average volume | 675.52K | 1.26M |
| Shares outstanding | 36.29M | 119.46M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
EVMN vs PYXS FAQ
Which is bigger, Evommune or Pyxis Oncology?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $240.11M compared with $225.74M for Evommune (EVMN).
Are Evommune and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.